drugset / Trial / NCT00699426
The Effect of Nexium and Probiotics on Insulin Secretion and Cardiovascular Risk Factors in Patients With Type 2 Diabetes
Phase 3
Completed
41 enrolled
Lise Tarnow
Novo Nordisk A/S · collabNovonesis · collabStatens Serum Institut · collabSteno Diabetes Center Copenhagen · collab
RandomizedFactorialQuadruple-blindTreatment
Summary
To test the effect of Nexium and probiotics on insulin secretion and cardiovascular risk factors on type 2 diabetic patients. Study Hypothesis: 1. Nexium causes an increased gastrin secretion that increases the insulin secretion and thereby a reduction of HbA1c 2. Probiotics changes the gut flora and bloodpressure 3. Probiotics causes a change in inflammation and thrombosis.
Timeline
- Start
- 2008-06
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Esomeprazole | Small molecule | 40 mg | — |